Changes in HIV-specific antibody responses and neutralization titers in patients under ART

Frontiers in Bioscience

Volumn 12, Issue 6, 2007, Pages 2148-2158

  Falkensammer, Barbara ^a   Freißmuth, Doris ^a   Hübner, Luzia ^a   Speth, Cornelia ^a   Dierich, Manfred Paul ^a   Stoiber, Heribert ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Antibody response; Antiretroviral Therapy; HIV; Human immunodeficiency virus; Immune system; Immunity; Neutralization; Virus

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE; TRANSACTIVATOR PROTEIN; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

ARTICLE; BLOOD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; SERODIAGNOSIS;

ANTIBODIES, VIRAL; GENE PRODUCTS, TAT; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; PEPTIDES; VIRAL ENVELOPE PROTEINS;

EID: 36049026738     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2218     Document Type: Article

References (40)

1. H. C. Lane & A. S. Fauci: Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 3, 477-500 (1985)
2. R. Yarchoan, R. R. Redfield & S. Broder: Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest 78, 439-447 (1986) (Pubitemid 16074081)
3. F. Miedema, A. J. Petit, F. G. Terpstra, J. K. Schattenkerk, F. de Wolf, J. M. Bert, M. Roos, J. M. Lange, S. A. Danner, J. Goudsmit & P. T. Schellekens.: Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 82, 1908-1914 (1988) (Pubitemid 19054937)
4. A. Amadori & L. Chieco-Bianchi: B-cell activation and HIV-1 infection: deeds and misdeeds. Immunol Today 11, 374-379 (1990) (Pubitemid 20292169)
5. R. Zamarchi, A. Barelli, A. Borri, G. Petralia, L. Ometto, S. Masiero, L. Chieco-Bianchi & A. Amadori: B cell activation in peripheral blood and lymph nodes during HIV infection. AIDS 16, 1217-1226 (2002) (Pubitemid 34666655)
6. L. Morris, J. M. Binley, B. A. Clas, S. Bonhoeffer, T. P. Astill, R. Kost, A. Hurley, Y. Cao, M. Markowitz, D. D. Ho & J. P. Moore: HIV-1 antigen-specific and-nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 188, 233-245 (1998) (Pubitemid 28357752)
7. D. W. Notermans, J. J. de Jong, J. Goudsmit, M. Bakker, M. T. Roos, L. Nijholt, J. Cremers, J. A. Hellings, S. A. Danner & A. de Ronde: Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses. AIDS Res Hum Retroviruses 17, 1003-1008 (2001) (Pubitemid 32881319)
8. M. Markowitz, M. Vesanen, K. Tenner-Racz, Y. Cao, J. M. Binley, A. Talal, A. Hurley, X. Jin, M. R. Chaudhry, M. Yaman, S. Frankel, M. Heath-Chiozzi, J. M. Leonard, J. P. Moore, P. Racz, D. F. Nixon & D. D. Ho: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 179, 527-537 (1999) (Pubitemid 30016135)
9. A. M. Fournier, V. Baillat, C. Alix-Panabieres, J. M. Fondere, C. Merle, M. Segondy, M. F. Huguet, J. Reynes & J. P. Vendrell: Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. AIDS 16, 1755-1760 (2002)
10. J. M. Binley, A. Trkola, T. Ketas, D. Schiller, B. Clas, S. Little, D. Richman, A. Hurley, M. Markowitz & J. P. Moore: The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection. J Infect Dis 182, 945-949 (2000)
11. M. A. Jacobson, H. Khayam-Bashi, J. N. Martin, D. Black & V. Ng: Effect of long-term highly active antiretroviral therapy in restoring HIV-induced abnormal B-lymphocyte function. J Acquir Immune Defic Syndr 31, 472-477 (2002) (Pubitemid 35448653)
12. Trkola A, Kuster H, Leemann C, Oxenius A, Fagard C, Furrer H, Battegay M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Bonhoeffer S, Gunthard HF; Swiss HIV Cohort Study. Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood 104, 1784-92 (2004) (Pubitemid 39202288)
13. L. Kacani, H. Stoiber & M. P. Dierich: Role of IL-15 in HIV-1-associated hypergammaglobulinaemia. Clin Exp Immunol 108, 14-18 (1997) (Pubitemid 27140324)
14. F. Barin, M. F. McLane, J. S. Allan, T. H. Lee, J. E. Groopman & M. Essex: Virus envelope protein of HTLVIII represents major target antigen for antibodies in AIDS patients. Science 228, 1094-1096 (1985) (Pubitemid 15227369)
15. U. Wieland, J. E. Kuhn, C. Jassoy, H. Rubsamen-Waigmann, V. Wolber & R. W. Braun: Antibodies to recombinant HIV-1 vif, tat, and nef proteins in human sera. Med Microbiol Immunol (Berl) 179, 1-11 (1990) (Pubitemid 20070693)
16. L. D. Loomis-Price, J. H. Cox, J. R. Mascola, T. C. VanCott, N. L. Michael, T. R. Fouts, R. R. Redfield, M. L. Robb, B. Wahren, H. W. Sheppard & D. L. Birx: Correlation between humoral responses to human immunodeficiency virus type 1 envelope and disease progression in early-stage infection. J Infect Dis 178, 1306-1316 (1998)
17. P. C. Chien Jr, S. Cohen, C. Kleeberger, J. Giorgi, J. Phair, S. Zolla-Pazner & C. E. Hioe: High levels of antibodies to the CD4 binding domain of human immunodeficiency virus type 1 glycoprotein 120 are associated with faster disease progression. J Infect Dis 186, 205-213 (2002) (Pubitemid 34765508)
18. C. Moog, H. J. Fleury, I. Pellegrin, A. Kirn & A. M. Aubertin: Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 71, 3734-3741 (1997) (Pubitemid 27172386)
19. D. Burton: Antibodies, viruses and vaccines. Nat Rev Immunol 2, 706-13 (2002) (Pubitemid 37328728)
20. E. Hogervorst, S. Jurriaans, F. de Wolf, A. van Wijk, A. Wiersma, M. Valk, M. Roos, B. van Gemen, R. Coutinho, F. Miedema, et al.: Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels. J Infect Dis 171, 811-821 (1995)
21. G. Zwart, L. van der Hoek, M. Valk, M. T. Cornelissen, E. Baan, J. Dekker, M. Koot, C. L. Kuiken & J. Goudsmit: Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 201, 285-293 (1994) (Pubitemid 24187273)
22. P. Reiss, F. de Wolf, C. L. Kuiken, A. de Ronde, J. Dekker, C. A. Boucher, C. Debouck, J. M. Lange & J. Goudsmit: Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr 4, 165-172 (1991)
23. M. C. Re, D. Gibellini, F. Vitone & M. La Placa: Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review. New Microbiol 24, 197-205 (2001) (Pubitemid 33633212)
24. C. Pedersen, C. M. Nielsen, B. F. Vestergaard, J. Gerstoft, K. Krogsgaard & J. O. Nielsen: Temporal relation of antigenaemia and loss of antibodies to core antigens to development of clinical disease in HIV infection. Br Med J (Clin Res Ed) 295, 567-569 (1987) (Pubitemid 17125347)
25. J. M. Lange, F. de Wolf, W. J. Krone, S. A. Danner, R. A. Coutinho & J. Goudsmit: Decline of antibody reactivity to outer viral core protein p17 is an earlier serological marker of disease progression in human immunodeficiency virus infection than anti-p24 decline. AIDS 1, 155-9 (1987) (Pubitemid 18014589)
26. J. C. Gea-Banacloche & H. Clifford Lane: Immune reconstitution in HIV infection. AIDS 13, Suppl A:S25-38 (1999)
27. B. Autran, G. Carcelain & P. Debre: Immune reconstitution after highly active anti-retroviral treatment of HIV infection. Adv Exp Med Biol 495, 205-212 (2001) (Pubitemid 34106937)
28. G. Carcelain, P. Debre & B. Autran: Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 13, 483-488 (2001) (Pubitemid 32728483)
29. N. G. Pakker, D. W. Notermans, R. J. de Boer, M. T. Roos, F. de Wolf, A. Hill, J. M. Leonard, S. A. Danner, F. Miedema & P. T. Schellekens: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 4, 208-214 (1998) (Pubitemid 28137376)
30. Z. Q. Zhang, D. W. Notermans, G. Sedgewick, W. Cavert, S. Wietgrefe, M. Zupancic, K. Gebhard, K. Henry, L. Boies, Z. Chen, M. Jenkins, R. Mills, H. McDade, C. Goodwin, C. M. Schuwirth, S. A. Danner & A. T. Haase: Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A 95, 1154-1159 (1998) (Pubitemid 28124928)
31. Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA. Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy. Med Care 43, III15-22 (2005) (Pubitemid 41329367)
32. Torti C, Cologni G, Uccelli MC, Quiros-Roldan E, Imberti L, Airo P, Pirovano S, Patroni A, Tirelli V, Carosi G. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol 17, 279-86 (2004) (Pubitemid 38880427)
33. T. Muster, F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker & H. Katinger: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67, 6642-6647 (1993) (Pubitemid 23309131)
34. G. Stiegler, C. Armbruster, B. Vcelar, H. Stoiber, R. Kunert, N. L. Michael, L. L. Jagodzinski, C. Ammann, W. Jager, J. Jacobson, N. Vetter & H. Katinger: Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 16, 2019-2025 (2002) (Pubitemid 35205265)
35. M. Mühlbacher, M. Spruth, F. Siegel, R. Zangerl & M. P. Dierich: Longitudinal study of antibody reactivity against HIV-1 envelope and a peptide representing a conserved site on gp41 in HIV-1 infected patients. Immunobiology 200, 295-305 (1999) (Pubitemid 29292220)
36. K.Dreyer, E. G. Kallas, V. Planelles, D. Montefiori, M. P. McDermott, M. S. Hasan & T. G. Evans: Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 15, 1563-1571 (1999)
37. J. M. Binley, P. J. Klasse, Y. Cao, I. Jones, M. Markowitz, D. D. Ho & J. P. Moore: Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J Virol 71, 2799-2809 (1997) (Pubitemid 27119919)
38. M. Clerici, E. Seminari, F. Maggiolo, A. Pan, M. Migliorino, D. Trabattoni, F. Castelli, F. Suter, M. L. Fusi, L. Minoli, G. Carosi, R. Maserati & Master Group: Early and late effects of highly active antiretroviral therapy: a 2 year follow-up of antiviral-treated and antiviral-naive chronically HIV-infected patients. AIDS 16, 1767-1773 (2002)
39. E. Fanales-Belasio, A. Cafaro, A. Cara, D. R. Negri, V. Fiorelli, S. Butto, S. Moretti, M. T. Maggiorella, S. Baroncelli, Z. Michelini, A. Tripiciano, L. Sernicola, A. Scoglio, A. Borsetti, B. Ridolfi, R. Bona, P. Ten Haaft, I. Macchia, P. Leone, M. R. Pavone-Cossut, F. Nappi, E. Vardas, M. Magnani, E. Laguardia, A. Caputo, F. Titti & B. Ensoli.: HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol 21, 599-610 (2002) (Pubitemid 35155682)
40. B. Hirschel: Planned interruptions of anti-HIV treatment. Lancet Infect Dis 1, 53-59 (2001) (Pubitemid 33586041)